Claims for Patent: 11,174,481

Summary for Patent: 11,174,481

Title:	Targeting ligands
Abstract:	Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds that are useful in directing the compounds to the in vivo target. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to a therapeutic compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
Inventor(s):	Zhen Li, Tao Pei, Agnieszka Glebocka, Michael Lawler, Fred Fleitz, Erich Altenhofer, Pankaj Kumar
Assignee:	Arrowhead Pharmaceuticals Inc
Application Number:	US16/380,695
Patent Claims:	1. A compound having a structure selected from the group consisting of: or a pharmaceutically acceptable salt thereof, wherein R is an RNAi agent, Y is O or S, and Y′ is 0″, S″, or NH″. 2. The compound of claim 1, wherein Y is S. 3. The compound of claim 1, wherein Y is O. 4. The compound of claim 1, wherein Y′ is 0″.